Eli Lilly Quarterly Balance Sheet
NYSE: LLYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Eli Lilly financial position
As of Jun 30, 2026, Eli Lilly reported total assets of $142.28 billion, up 41.0% from a year earlier against total liabilities of $108.40 billion. Shareholders' equity stood at $33.88 billion, or 23.8% of assets. The company held $8.95 billion in cash and equivalents against $54.91 billion of debt, a net debt position of $45.96 billion.
The current ratio (current assets divided by current liabilities) was 1.35, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.62.
Summary generated from market data by MetaCap's automated system. Methodology
Eli Lilly balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.95B | 5.28B | 7.27B | 9.79B | 3.38B | 3.09B | 3.27B | 3.37B | 3.22B | 2.46B | 2.82B | 2.38B |
| Short-Term Investments | — | — | — | 121.60M | 170.10M | 127.40M | 154.80M | 149.40M | 140.40M | 126.10M | 109.10M | 113.10M |
| Receivables | 20.08B | 18.43B | 17.76B | 16.11B | 14.17B | 12.04B | 11.01B | 10.29B | 11.03B | 7.89B | 9.09B | 8.17B |
| Inventory | 16.79B | 14.53B | 13.74B | 12.18B | 11.01B | 9.31B | 7.59B | 7.46B | 6.48B | 6.10B | 5.77B | 4.90B |
| Total Current Assets | 64.67B | 54.84B | 55.63B | 62.07B | 49.85B | 41.26B | 32.74B | 31.42B | 30.20B | 25.19B | 25.73B | 23.01B |
| Property, Plant & Equipment | 29.29B | 26.54B | 24.68B | 22.32B | 20.53B | 18.47B | 17.10B | 16.17B | 14.83B | 13.62B | 12.91B | 11.86B |
| Goodwill | 8.85B | 6.13B | 5.90B | 5.90B | 5.77B | 5.77B | 5.77B | 5.77B | 5.77B | 4.94B | 4.94B | 4.09B |
| Intangible Assets | 18.11B | 7.37B | 6.52B | 6.45B | 5.91B | 6.01B | 6.17B | 6.54B | 6.64B | 6.76B | 6.91B | 6.78B |
| Long-Term Investments | 3.86B | 3.12B | 2.80B | 2.81B | 3.21B | 3.22B | 3.22B | 3.20B | 2.88B | 3.09B | 3.05B | 2.69B |
| Total Assets | 142.28B | 116.58B | 112.48B | 114.94B | 100.92B | 89.39B | 78.72B | 75.61B | 71.87B | 63.94B | 64.01B | 57.92B |
| Accounts Payable | 6.11B | 5.03B | 5.38B | 4.26B | 4.08B | 3.44B | 3.23B | 2.89B | 2.92B | 2.47B | 2.60B | 2.44B |
| Short-Term Debt | 7.05B | 4.00B | 1.64B | 1.63B | 5.72B | 4.02B | 5.12B | 2.07B | 5.16B | 1.65B | 6.90B | 2.24B |
| Total Current Liabilities | 47.74B | 36.63B | 35.23B | 40.14B | 39.02B | 30.07B | 28.38B | 24.67B | 27.12B | 18.60B | 27.29B | 22.00B |
| Long-Term Debt | 47.86B | 39.37B | 40.87B | 40.87B | 34.18B | 34.50B | 28.53B | 29.05B | 23.73B | 24.56B | 18.32B | 17.92B |
| Total Liabilities | 108.40B | 85.38B | 85.94B | 91.08B | 82.57B | 73.54B | 64.44B | 61.29B | 58.24B | 51.05B | 53.14B | 46.61B |
| Shareholders' Equity | 33.88B | 31.20B | 26.54B | 23.79B | 18.27B | 15.76B | 14.27B | 14.24B | 13.56B | 12.81B | 10.77B | 11.22B |
| Retained Earnings | 31.89B | 29.51B | 24.47B | 22.25B | 17.38B | 15.10B | 13.54B | 13.63B | 13.18B | 12.55B | 10.31B | 10.31B |
| Total Debt | 54.91B | 43.37B | 42.50B | 42.51B | 39.90B | 38.52B | 33.64B | 31.12B | 28.89B | 26.21B | 25.23B | 20.17B |
| Net Cash (Debt) | -45.96B | -38.09B | -35.23B | -32.59B | -36.36B | -35.30B | -30.22B | -27.60B | -25.53B | -23.63B | -22.30B | -17.67B |
This table shows 12 quarterly periods of Eli Lilly's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow LLY's reporting calendar. What is a balance sheet?